{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:25:45Z","timestamp":1772187945043,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction and objectives<\/jats:title>\n                    <jats:p>The specific risk factors contributing to coronary artery disease (CAD) in individuals with metabolic-associated fatty liver disease (MAFLD) have not been comprehensively examined. Given the critical role of inflammation in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD), the monocyte to high-density lipoprotein cholesterol ratio (MHR) has emerged as a novel and significant inflammatory biomarker linked to CAD. Therefore, the primary objective of this study was to identify the risk factors associated with CAD in the MAFLD population, to analyze and compare MHR levels in MAFLD patients with and without concurrent CAD, and to evaluate the diagnostic and predictive value of MHR for CAD incidence within this high-risk cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In total, 251 patients with MAFLD, comprising 151 individuals with CAD and 100 without CAD, were included in the study conducted at the First People's Hospital of Yangquan. The diagnosis of CAD was established through coronary angiography. Biochemical indices were collected and subjected to logistic regression analysis to identify markers that exhibited differential expression between MAFLD patients with CAD and those without CAD. These markers were subsequently integrated into a diagnostic model. The predictive efficacy of this model was evaluated using Decision Curve Analysis (DCA). Furthermore, the relationship between the MHR and other markers was examined using Spearman's correlation analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Gender, age, white blood cell count (WBC), total cholesterol (TC), and the MHR were identified as significant risk factors for CAD in patients with MAFLD. Based on the area under the curve (AUC) value, the diagnostic model incorporating these five risk factors demonstrated robust diagnostic performance, with an AUC of 0.809. The DCA further validated its diagnostic effectiveness. Additionally, MHR was found to possess substantial diagnostic value for the occurrence of CAD events in MAFLD patients, with an AUC of 0.701. Further analysis of MHR quartiles revealed that patients in the highest quartile exhibited a significantly elevated risk of CAD compared to those in the other three quartiles. Moreover, significant correlations were observed between MHR and body mass index, WBC, uric acid, creatinine and triglycerides.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings confirmed the importance of gender, age, WBC, TC, and MHR in predicting the occurrence of CAD in MAFLD populations, with MHR showing higher predictive value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1714942","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:31:36Z","timestamp":1772184696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors of coronary artery disease in metabolic-associated fatty liver disease: a single center cross-sectional study"],"prefix":"10.3389","volume":"13","author":[{"given":"Rui","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xumin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First People\u2019s Hospital of Yangquan","place":["Yangquan, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FenFang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First People\u2019s Hospital of Yangquan","place":["Yangquan, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","article-title":"An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/liv.15139","article-title":"Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups","volume":"42","author":"Ayada","year":"2022","journal-title":"Liver Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.3390\/jcm14072441","article-title":"Clinical and economic burden of metabolic dysfunction-associated steatotic liver disease (MASLD) in a Spanish Mediterranean region: a population-based study","volume":"14","author":"D\u00edaz Carnicero","year":"2025","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: how is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1097\/CM9.0000000000001513","article-title":"Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/ATVBAHA.122.318661","article-title":"Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study","volume":"43","author":"Sung","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.eclinm.2023.102292","article-title":"Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study","volume":"65","author":"Moon","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/hepr.13700","article-title":"Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease","volume":"51","author":"Tamaki","year":"2021","journal-title":"Hepatol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9237","DOI":"10.1002\/jcp.27028","article-title":"Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases","volume":"233","author":"Ganjali","year":"2018","journal-title":"J Cell Physiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1177\/1076029615594002","article-title":"Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation","volume":"22","author":"Canpolat","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"B15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12944-022-01741-8","article-title":"The blood monocyte to high density lipoprotein cholesterol ratio (MHR) is a possible marker of carotid artery plaque","volume":"21","author":"Xi","year":"2022","journal-title":"Lipids Health Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e3333","DOI":"10.1002\/dmrr.3333","article-title":"Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance","volume":"36","author":"Fiorentino","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e00011","DOI":"10.14309\/ctg.0000000000000011","article-title":"Impact of non-alcoholic fatty liver disease on cardiovascular outcomes in patients with stable coronary artery disease: a matched case-control study","volume":"10","author":"Liu","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/eurheartj\/ehr453","article-title":"Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?","volume":"33","author":"Bhatia","year":"2012","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/hep4.1760","article-title":"Nonalcoholic fatty liver disease prevalence trends among adolescents and young adults in the United States, 2007-2016","volume":"5","author":"Arshad","year":"2021","journal-title":"Hepatol Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.atherosclerosis.2013.01.013","article-title":"Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease","volume":"227","author":"Feitosa","year":"2013","journal-title":"Atherosclerosis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jcmg.2016.02.001","article-title":"Sex differences in demographics, risk factors, presentation, and noninvasive testing in stable outpatients with suspected coronary artery disease: insights from the PROMISE trial","volume":"9","author":"Hemal","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"B25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.5009\/gnl18439","article-title":"Noninvasive serum fibrosis markers are associated with coronary artery calcification in patients with nonalcoholic fatty liver disease","volume":"13","author":"Song","year":"2019","journal-title":"Gut Liver"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s10620-018-5006-7","article-title":"Pronounced coronary arteriosclerosis in cirrhosis: influence on cardiac function and survival?","volume":"63","author":"Danielsen","year":"2018","journal-title":"Dig Dis Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101109","DOI":"10.1016\/j.plipres.2021.101109","article-title":"Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis","volume":"83","author":"Li","year":"2021","journal-title":"Prog Lipid Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cmet.2024.09.009","article-title":"Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation","volume":"37","author":"Lam","year":"2025","journal-title":"Cell Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.atherosclerosis.2011.12.038","article-title":"White blood cell count is associated with carotid and femoral atherosclerosis","volume":"221","author":"Ortega","year":"2012","journal-title":"Atherosclerosis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5287580","DOI":"10.1155\/2024\/5287580","article-title":"Association of monocyte-to-HDL cholesterol ratio with endothelial dysfunction in patients with type 2 diabetes","volume":"2024","author":"Zhang","year":"2024","journal-title":"J Diabetes Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.tcm.2025.01.001","article-title":"Metabolic dysfunction-associated steatotic liver disease and the cardiovascular system","volume":"35","author":"Manolis","year":"2025","journal-title":"Trends Cardiovasc Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4103\/njcp.njcp_252_24","article-title":"The importance of monocyte-to-high density lipoprotein-cholesterol ratio in predicting severity of coronary artery disease in acute coronary syndrome","volume":"28","author":"Kaynak","year":"2025","journal-title":"Niger J Clin Pract"},{"key":"B35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/JIR.S501787","article-title":"Association of the monocyte to high-density lipoprotein cholesterol ratio and neutrophil to high-density lipoprotein cholesterol ratio with the severity of new-onset coronary artery disease","volume":"18","author":"Shu","year":"2025","journal-title":"J Inflamm Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e4181","DOI":"10.1136\/bmj.e4181","article-title":"Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2","volume":"344","author":"Collins","year":"2012","journal-title":"Br Med J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e86910","DOI":"10.7759\/cureus.86910","article-title":"Applicability and risk stratification of QRISK\u00ae, framingham risk score, systematic coronary risk evaluation (SCORE), and American College of Cardiology\/American Heart Association (ACC\/AHA) risk assessment tools among patients in Taif, Saudi Arabia","volume":"17","author":"Alnefaie","year":"2025","journal-title":"Cureus"},{"key":"B38","doi-asserted-by":"publisher","first-page":"755806","DOI":"10.3389\/fcvm.2021.755806","article-title":"Adjustment of the GRACE risk score by monocyte to high-density lipoprotein ratio improves prediction of adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"8","author":"Ma","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"7325","DOI":"10.2147\/JIR.S479253","article-title":"Analysis of the clinical predictive value of the novel inflammatory indices SII, SIRI, MHR and NHR in patients with acute myocardial infarction and their extent of coronary artery disease","volume":"17","author":"Sun","year":"2024","journal-title":"J Inflamm Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.47176\/mjiri.35.85","article-title":"Investigating the relationship between the severity of coronary artery disease and inflammatory factors of MHR, PHR, NHR, and IL-25","volume":"35","author":"Manoochehri","year":"2021","journal-title":"Med J Islam Repub Iran"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1714942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:31:39Z","timestamp":1772184699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1714942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2026.1714942"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1714942","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1714942"}}